# Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

> **NCT02826603** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1114 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Secukinumab
- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT02826603
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-22
- **Primary completion:** 2018-07-09
- **Final completion:** 2018-07-09
- **Target enrollment:** 1114 (ACTUAL)
- **Last updated:** 2019-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02826603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02826603, "Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02826603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*